| Recruiting | 3 | 186 | Europe, US | Daromun, Surgery, Adjuvant therapy | Philogen S.p.A., Philogen S.p.A. | Melanoma Stage IIIB/C | 06/24 | 06/26 | | |
| Suspended | 2 | 6 | US | T-Vec, talimogene laherparepvec, Amgen | University of California, Davis, Amgen | Melanoma | 06/22 | 05/24 | | |
NCT02964559: Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer |
|
|
| Completed | 2 | 11 | US | Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475 | Emory University, Merck Sharp & Dohme LLC, National Institutes of Health (NIH), National Cancer Institute (NCI) | Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma | 05/21 | 05/21 | | |
NCT03769155: VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma |
|
|
| Active, not recruiting | 1 | 41 | US | Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, VX15/2503, moAb VX15/2503, Pepinemab, Surgery | Emory University, Bristol-Myers Squibb, Vaccinex Inc., National Institutes of Health (NIH), National Cancer Institute (NCI) | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | 12/23 | 12/32 | | |